Pre-made Faricimab benchmark antibody ( Bispecific mAb, anti-VEGFA;ANGPT2 therapeutic antibody, Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Faricimab (INN) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-204-1mg	1mg	Inquiry
GMP-Bios-ab-204-10mg	10mg	Inquiry
GMP-Bios-ab-204-100mg	100mg	Inquiry
GMP-Bios-ab-204-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody
INN Name	Faricimab
Target	VEGFA;ANGPT2
Format	Bispecific mAb
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	1cz8:HL:YX;None
99% SI Structure	None;None
95-98% SI Structure	1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC
Year Proposed	2017
Year Recommended	2018
Companies	Chugai Pharmaceutical;Roche
Conditions Approved	na
Conditions Active	Diabetic macular oedema;Wet age-related macular degeneration;Retinal oedema
Conditions Discontinued	na
Development Tech	Dual-Affinity Re-Targeting Technology